Lysogene announced the nomination of Dr. Ralph Laufer as Chief Scientific Officer and member of the executive team. Dr. Ralph Laufer brings over 25 years of industry experience in drug discovery, translational research and drug development at large pharmaceutical and biotechnology companies. Before joining Lysogene, Dr. Ralph Laufer was Senior Vice President at Teva Pharmaceutical Industries in Israel, where he managed small molecule discovery, nonclinical development and CMC, leading a team of over 400 scientists in 5 global sites. Prior to that, he was the Scientific Director of IRBM Science Park, a drug discovery CRO and biotech company in Rome, Italy. Previously, Dr. Laufer was Head of Pharmacology at IRBM-Merck Research Laboratories Rome. He is the recipient of the American Chemical Society 2013 Heroes of Chemistry Award for his role in the discovery of IsentressTM (raltegravir), the first integrase inhibitor approved for use in HIV infected patients.